"Designing Growth Strategies is in our DNA"
Fibromuscular dysplasia (FMD) is a disease characterized by abnormal growth of the cells in the walls of the arteries, which thickens, narrows and even enlarges the arteries making the blood flow difficult. Fibromuscular dysplasia (FMD) often affects the renal arteries, carotid arteries, abdominal arteries and arteries of arms and legs.
The cause of fibromuscular dysplasia (FMD) disease is unknown but some of the factors considered for the cause are genetic, change in hormones and lack of oxygen supply to the arteries. At present, there is no cure for fibromuscular dysplasia. Current treatments for FMD include surgical revascularization, percutaneous transluminal angioplasty (PTA), and drugs like angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers among others.
To gain extensive insights into the market, Request for Customization
The rise in the prevalence of hypertension among the global population and sedentary lifestyle owing to the rising prevalence of fibromuscular dysplasia. Increasing prevalence of smoking is leading to a higher risk of the fibromuscular dysplasia acroos the globe. The Centers for Disease Control and Prevention stated that in 14% of the adults in the U.S were smokers in the year 2017. This is one major factor expected to present a large patient pool requiring treatment and will drive the growth of the global fibromuscular dysplasia (FMD) treatment market during the forecast period.
However, side effects of the treatment to the patients, lack of robust healthcare infrastructure in emerging countries and presence generic drugs in the market are some of the major restraining factors of the global fibromuscular dysplasia (FMD) treatment market.
Some of the major companies that are present in the global fibromuscular dysplasia (FMD) treatment market are ALVOGEN, Aspen Surgical Products, Inc., AstraZeneca, B. Braun Melsungen AG, Bayer Healthcare Pharmaceuticals Inc., Becton, Dickinson and Company, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co., Ltd, Ethicon, Inc., Merck, Novartis, Pfizer, Sanofi-Aventis, Smith & Nephew plc; Medtronic, Stryker Corporation, and Watson Pharma Private Limited.
By Drug Class
· Angiotensin-converting enzyme (ACE) inhibitors
· Angiotensin II receptor blockers
· Calcium channel blockers
By Distribution Channel
· Hospitals pharmacies
· Retail pharmacies
· Online pharmacies
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Among drug class segmentation angiotensin-converting enzyme (ACE) inhibitors are projected to dominate the global fibromuscular dysplasia treatment market owing to greater efficacy offered by the drug.
The global fibromuscular dysplasia treatment market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America is estimated to account for the largest share in the global fibromuscular dysplasia (FMD) treatment market in 2018, owing to the increasing prevalence of fibromuscular dysplasia (FMD), rising prevalence of smoking among the general population, and rising investments in R&D to understand the progression of fibromuscular dysplasia. Asia Pacific is expected to gain market share from 2019-2026, owing to a higher prevalence of hypertension and smoking, increasing per capita healthcare expenditure leading to higher demand for new and advanced treatments for fibromuscular dysplasia (FMD). Additionally, the fibromuscular dysplasia treatment market is estimated to grow positively in this region owing to the rise in government initiatives taken towards awareness about the symptoms of the disease.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry